Usefulness of combining galectin-3 and BIVA assessments in predicting short- and long-term events in patients admitted for acute heart failure

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  De Berardinis, Benedetta ^a   Magrini, Laura ^a   Zampini, Giorgio ^a   Zancla, Benedetta ^a   Salerno, Gerardo ^a   Cardelli, Patrizia ^a   Di Stasio, Enrico ^b   Gaggin, Hanna K ^c   Belcher, Arianna ^c   Parry, Blair A ^c   Nagurney, John T ^c   Januzzi, James L ^c   Di Somma, Salvatore ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; GALECTIN 3;

ACUTE HEART FAILURE; AGED; AREA UNDER THE CURVE; ARTICLE; BIOIMPEDANCE VECTOR ANALYSIS; DEATH; EMERGENCY WARD; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HOSPITAL ADMISSION; HOSPITAL READMISSION; HUMAN; IMPEDANCE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PROGNOSIS; TREATMENT DURATION; ACUTE DISEASE; BLOOD; HEART FAILURE; MORTALITY; PATHOLOGY; RISK FACTOR; VERY ELDERLY;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; ELECTRIC IMPEDANCE; FEMALE; GALECTIN 3; HEART FAILURE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; NATRIURETIC PEPTIDE, BRAIN; RISK FACTORS;

EID: 84904801975     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/983098     Document Type: Article

References (31)

1. Krumholz H. M., Merrill A. R., Schone E. M., Patterns of hospital performance in acute myocardial infarction and heart failure 30-day mortality and readmission. Circulation: Cardiovascular Quality and Outcomes 2009 2 5 407 413 2-s2.0-74049105740 10.1161/CIRCOUTCOMES.109.883256
2. Desai A. S., Stevenson L. W., Rehospitalization for heart failure: predict or prevent? Circulation 2012 126 4 501 506 2-s2.0-84864241198 10.1161/CIRCULATIONAHA.112.125435
3. Shah R. V., Chen-Tournoux A. A., Picard M. H., van Kimmenade R. R., Januzzi J. L., Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. European Journal of Heart Failure 2010 12 8 826 832 2-s2.0-77955463871 10.1093/eurjhf/hfq091
4. van Kimmenade R. R., Januzzi J. L. Jr., Ellinor P. T., Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. Journal of the American College of Cardiology 2006 48 6 1217 1224 2-s2.0-33748415221 10.1016/j.jacc.2006.03.061 (Pubitemid 44345127)
5. López E., del Pozo V., Miguel T., Inhibition of chronic airway inflammation and remodeling by galectin-3 gene therapy in a murine model. The Journal of Immunology 2006 176 3 1943 1950 2-s2.0-31144445789 (Pubitemid 43134340)
6. Gheorghiade M., Follath F., Ponikowski P., Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European society of cardiology and endorsed by the European society of intensive care medicine. European Journal of Heart Failure 2010 12 5 423 433 2-s2.0-77957227912 10.1093/eurjhf/hfq045
7. Piccoli A., Codognotto M., Cianci V., Differentiation of cardiac and noncardiac dyspnea using bioelectrical impedance vector analysis (BIVA). Journal of Cardiac Failure 2012 18 3 226 232 2-s2.0-84857911878 10.1016/j.cardfail. 2011.11.001
8. Di Somma S., de Berardinis B., Bongiovanni C., Marino R., Ferri E., Alfei B., Use of BNP and bioimpedance to drive therapy in heart failure patients. Congestive Heart Failure 2010 16 supplement 1 S56 S61 2-s2.0-77955135877 10.1111/j.1751-7133.2010.00162.x
9. Di Somma S., Lalle I., Magrini L., Additive diagnostic and prognostic value of Bioelectrical Impedance Vector Analysis (BIVA) to brain natriuretic peptide "grey-zone" in patients with acute heart failure in the emergency department. European Heart Journal: Acute Cardiovascular Care 2014 3 2 167 175 10.1177/2048872614521756
10. McMurray J. J., Adamopoulos S., Anker S. D., ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Heart Journal 2012 33 14 1787 1847 2-s2.0-84864493727 10.1093/eurheartj/ehs104
11. Levey A. S., Bosch J. P., Lewis J. B., Greene T., Rogers N., Roth D., A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in Renal Disease Study Group. Annals of Internal Medicine 1999 130 6 461 470 2-s2.0-0033574249 (Pubitemid 29135798)
12. McCullough P. A., Olobatoke A., Vanhecke T. E., Galectin-3: a novel blood test for the evaluation and management of patients with heart failure. Reviews in Cardiovascular Medicine 2011 12 4 200 210 10.3909/ricm0624
13. Whellan D. J., O'Connor C. M., Lee K. L., Heart failure and a controlled trial investigating outcomes of exercise training (HF-ACTION): design and rationale. American Heart Journal 2007 153 2 201 211 2-s2.0-33846263440 10.1016/j.ahj.2006.11.007 (Pubitemid 46096868)
14. Valle R., Aspromonte N., Milani L., Optimizing fluid management in patients with acute decompensated heart failure (ADHF): the emerging role of combined measurement of body hydration status and brain natriuretic peptide (BNP) levels. Heart Failure Reviews 2011 16 6 519 529 2-s2.0-80052439267 10.1007/s10741-011-9244-4
15. Kushner R. F., Bioelectrical impedance analysis: a review of principles and applications. Journal of the American College of Nutrition 1992 11 2 199 209 2-s2.0-0026591568
16. Piccoli A., Bioelectric impedance vector distribution in peritoneal dialysis patients with different hydration status. Kidney International 2004 65 3 1050 1063 2-s2.0-1342322643 10.1111/j.1523-1755.2004.00467.x (Pubitemid 38251081)
17. Lukaski H. C., Johnson P. E., Bolonchuk W. W., Lykken G. I., Assessment of fat-free mass using bioelectrical impedance measurements of the human body. The American Journal of Clinical Nutrition 1985 41 4 810 817 2-s2.0-0021911516 (Pubitemid 15092891)
18. de Boer R. A., Yu L., van Veldhuisen D. J., Galectin-3 in cardiac remodeling and heart failure. Current Heart Failure Reports 2010 7 1 1 8 2-s2.0-77449109919 10.1007/s11897-010-0004-x
19. Maisel A., Mueller C., Adams K. Jr., State of the art: using natriuretic peptide levels in clinical practice. European Journal of Heart Failure 2008 10 9 824 839 2-s2.0-51549120537 10.1016/j.ejheart.2008.07.014
20. de Boer R. A., Voors A. A., Muntendam P., van Gilst W. H., van Veldhuisen D. J., Galectin-3: a novel mediator of heart failure development and progression. European Journal of Heart Failure 2009 11 9 811 817 2-s2.0-69249134131 10.1093/eurjhf/hfp097
21. Milting H., Ellinghaus P., Seewald M., Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. Journal of Heart and Lung Transplantation 2008 27 6 589 596 2-s2.0-44149110139 10.1016/j.healun.2008.02. 018 (Pubitemid 351715387)
22. de Boer R. A., Lok D. J., Jaarsma T., Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Annals of Medicine 2011 43 1 60 68 2-s2.0-78651387589 10.3109/07853890.2010. 538080
23. Lainscak M., Coletta A. P., Sherwi N., Cleland J. G., Clinical trials update from the Heart Failure Society of America Meeting 2009: FAST, IMPROVE-HF, COACH galectin-3 substudy, HF-ACTION nuclear substudy, DAD-HF, and MARVEL-1. European Journal of Heart Failure 2010 12 2 193 196 2-s2.0-75149130005 10.1093/eurjhf/hfp185
24. Tang W. H., Shrestha K., Shao Z., Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. American Journal of Cardiology 2011 108 3 385 390 2-s2.0-79960350455 10.1016/j.amjcard. 2011.03.056
25. Lok D. J. A., van der Meer P., de la Porte P. W., Prognostic value of galectin-3, a novel marker of fibrosis,in patients with chronic heart failure: data from the DEAL-HF study. Clinical Research in Cardiology 2010 99 5 323 328 2-s2.0-77954658143 10.1007/s00392-010-0125-y
26. van der Velde A. R., Gullestad L., Ueland T., Prognostic value of changes in galectin-3 levels over time in patients with heart failure data from CORONA and COACH. Circulation: Heart Failure 2013 6 2 219 226 2-s2.0-84877246724 10.1161/CIRCHEARTFAILURE.112.000129
27. Bayes-Genis A., de Antonio M., Vila J., Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. Journal of the American College of Cardiology 2014 63 2 158 166 10.1016/j.jacc.2013.07.087
28. Meijers W. C., Januzzi J. L., deFilippi C., Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials. American Heart Journal 2014 167 6 853.e4 860.e4 10.1016/j.ahj.2014.02.011
29. Di Somma S., Magrini L., Pittoni V., In-hospital percentage BNP reduction is highly predictive for adverse events in patients admitted for acute heart failure: the Italian RED Study. Critical Care 2010 14 3, article R116 2-s2.0-77953401339 10.1186/cc9067
30. O'Seaghdha C. M., Hwang S. J., Ho J. E., Vasan R. S., Levy D., Fox C. S., Elevated galectin-3 precedes the development of CKD. Journal of the American Society of Nephrology 2013 24 9 1470 1477 10.1681/ASN.2012090909
31. Sharma U. C., Pokharel S., van Brakel T. J., Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004 110 19 3121 3128 2-s2.0-20844462878 10.1161/01.CIR.0000147181.65298.4D (Pubitemid 39492008)